304 related articles for article (PubMed ID: 20574050)
1. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Broyl A; Hose D; Lokhorst H; de Knegt Y; Peeters J; Jauch A; Bertsch U; Buijs A; Stevens-Kroef M; Beverloo HB; Vellenga E; Zweegman S; Kersten MJ; van der Holt B; el Jarari L; Mulligan G; Goldschmidt H; van Duin M; Sonneveld P
Blood; 2010 Oct; 116(14):2543-53. PubMed ID: 20574050
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
3. The molecular classification of multiple myeloma.
Zhan F; Huang Y; Colla S; Stewart JP; Hanamura I; Gupta S; Epstein J; Yaccoby S; Sawyer J; Burington B; Anaissie E; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Walker R; Zangari M; Crowley J; Barlogie B; Shaughnessy JD
Blood; 2006 Sep; 108(6):2020-8. PubMed ID: 16728703
[TBL] [Abstract][Full Text] [Related]
4. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.
van Laar R; Flinchum R; Brown N; Ramsey J; Riccitelli S; Heuck C; Barlogie B; Shaughnessy JD
BMC Med Genomics; 2014 May; 7():25. PubMed ID: 24885236
[TBL] [Abstract][Full Text] [Related]
5. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Zhan F; Hardin J; Kordsmeier B; Bumm K; Zheng M; Tian E; Sanderson R; Yang Y; Wilson C; Zangari M; Anaissie E; Morris C; Muwalla F; van Rhee F; Fassas A; Crowley J; Tricot G; Barlogie B; Shaughnessy J
Blood; 2002 Mar; 99(5):1745-57. PubMed ID: 11861292
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
Zhan F; Tian E; Bumm K; Smith R; Barlogie B; Shaughnessy J
Blood; 2003 Feb; 101(3):1128-40. PubMed ID: 12393520
[TBL] [Abstract][Full Text] [Related]
7. CD138
Shuai W; Li S
Blood; 2019 Sep; 134(11):906. PubMed ID: 31515228
[No Abstract] [Full Text] [Related]
8. Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics.
Toman I; Loree J; Klimowicz AC; Bahlis N; Lai R; Belch A; Pilarski L; Reiman T
Leuk Lymphoma; 2011 Apr; 52(4):659-67. PubMed ID: 21438833
[TBL] [Abstract][Full Text] [Related]
9. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.
Martello M; Remondini D; Borsi E; Santacroce B; Procacci M; Pezzi A; Dico FA; Martinelli G; Zamagni E; Tacchetti P; Pantani L; Testoni N; Marzocchi G; Rocchi S; Zannetti BA; Mancuso K; Cavo M; Terragna C
Leukemia; 2016 Sep; 30(9):1869-76. PubMed ID: 27074969
[TBL] [Abstract][Full Text] [Related]
10. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
van Duin M; Broyl A; de Knegt Y; Goldschmidt H; Richardson PG; Hop WC; van der Holt B; Joseph-Pietras D; Mulligan G; Neuwirth R; Sahota SS; Sonneveld P
Haematologica; 2011 Nov; 96(11):1662-9. PubMed ID: 21791470
[TBL] [Abstract][Full Text] [Related]
11. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of molecular subtyping multiple myeloma using gene expression profiling.
Weinhold N; Heuck CJ; Rosenthal A; Thanendrarajan S; Stein CK; Van Rhee F; Zangari M; Hoering A; Tian E; Davies FE; Barlogie B; Morgan GJ
Leukemia; 2016 Feb; 30(2):423-30. PubMed ID: 26526987
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
14. [Gene expression profiling of multiple myeloma].
Minvielle S
Bull Cancer; 2003 Feb; 90(2):127-30. PubMed ID: 12660131
[TBL] [Abstract][Full Text] [Related]
15. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Chng WJ; Kumar S; Vanwier S; Ahmann G; Price-Troska T; Henderson K; Chung TH; Kim S; Mulligan G; Bryant B; Carpten J; Gertz M; Rajkumar SV; Lacy M; Dispenzieri A; Kyle R; Greipp P; Bergsagel PL; Fonseca R
Cancer Res; 2007 Apr; 67(7):2982-9. PubMed ID: 17409404
[TBL] [Abstract][Full Text] [Related]
16. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
Merz M; Jauch A; Hielscher T; Bochtler T; Schönland SO; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Hillengass J; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf IGH; Scheid C; Haenel M; Weisel KC; Goldschmidt H
Blood Adv; 2018 Jan; 2(1):1-9. PubMed ID: 29344579
[TBL] [Abstract][Full Text] [Related]
18. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Boyle EM; Rosenthal A; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Davies FE; Walker BA; van Rhee F; Morgan GJ
Br J Haematol; 2021 Oct; 195(2):283-286. PubMed ID: 34244996
[No Abstract] [Full Text] [Related]
19. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma.
Dementyeva E; Kryukov F; Kubiczkova L; Nemec P; Sevcikova S; Ihnatova I; Jarkovsky J; Minarik J; Stefanikova Z; Kuglik P; Hajek R
J Transl Med; 2013 Mar; 11():77. PubMed ID: 23522059
[TBL] [Abstract][Full Text] [Related]
20. Robust isolation of malignant plasma cells in multiple myeloma.
Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
